New Data Supports Efficacy and Safety of Celltrion’s Rituximab Biosimilar

Biosimilar News

Celltrion Healthcare presented new data on their Rituximab biosimilar Truxima® (CT-P10) at the International Conference on Malignant Lymphoma (ICML) in Switzerland and the European League Against Rheumatism (EULAR) Congress 2017 in Spain.  According to the presentation, data from a randomized, double-blind, controlled phase III study in 140 patients indicate that Truxima® is comparable to reference rituximab in efficacy and safety for both oncology and autoimmune indications.

Download PDF

Comments are closed.